Alzheimer's Disease
Filter News
Found 1,078 articles
-
Eisai and Biogen announced positive updates on the Phase IIB 201 and open-label extension studies they are conducting on the use of lecanemab to treat early Alzheimer's Disease.
-
AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.
-
The company is investigating the death of a 75-year-old woman who died of ARIA while receiving Aduhelm.
-
Sungho Han, Ph.D., founder and CEO of Genuv Inc. in Seoul, South Korea, has built her career and her company by thinking outside the box.
-
Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference
11/10/2021
Athira Pharma, Inc. today announced that Hans Moebius, M.D., Ph.D., Chief Medical Officer at Athira, presented an overview and updates from two ongoing late-stage clinical trials (ACT-AD and LIFT-AD) with Athira’s lead development candidate ATH-1017 in mild-to-moderate Alzheimer’s disease
-
Novoic presents symposium together with the Alzheimer's Drug Discovery Foundation on the Next Generation of Speech Biomarkers for the Early Detection of Alzheimer's Disease at Clinical Trials in Alzheimer's Disease (CTAD) Conference
11/10/2021
Novoic Ltd, a clinical stage digital medtech company developing speech- and language-based biomarkers for neurological disease, has presented a scientific symposium together with the Alzheimer's Drug Discovery Foundation's Diagnostic Accelerator at the 14th Annual Clinical Trials on Alzheimer's Disease in Boston, MA, USA.
-
Research into Alzheimer’s disease is shifting from amyloid plaque and tau protein to neuroinflammation, white matter changes and insulin resistance.
-
Amylyx Pharmaceuticals Announces Results from PEGASUS Trial of AMX0035 in Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
11/9/2021
Amylyx Pharmaceuticals, Inc. today presented clinical data from the Phase 2 Trial AMX-8000 (PEGASUS) trial of AMX0035 (sodium phenylbutyrate (PB) and taurursodiol (TURSO; also known as ursodoxicoltaurine) for the treatment of Alzheimer’s disease (AD).
-
Keystone Bio Recognizes the Big "GAIN" from Cortexyme's Trial Results
11/9/2021
Keystone Bio acknowledges Cortexyme's efforts in advancing Alzheimer’s disease research through its recently published Ph ll/lll GAIN Trial preliminary results.
-
Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
11/9/2021
Poster highlighting the mechanism of action for ANVS401 is on display onsite and online.
-
DIAN-TU Selects Lecanemab As Background Anti-Amyloid Therapy In Clinical Trial Evaluating Investigational Therapy Targeting Tau For Dominantly Inherited Alzheimer's Disease
11/8/2021
Eisai Co., Ltd. announced that the Dominantly Inherited Alzheimer Network Trials Unit, led by Washington University School of Medicine in St. Louis, has an agreement with the U.S. Food and Drug Administration and the European Medicines Agency to amend the clinical study design to include a background anti-amyloid agent.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA at the CTAD Meeting in Boston
11/5/2021
South Korean bio-venture BIORCHESTRA Co. Ltd., is an RNA therapeutics firm focused on neurodegeneration. BIORCHESTRA discovered a disease-associated microRNA that was found to be significantly up-regulated in samples from Alzheimer's disease patients.
-
Researchers with the University of Cambridge in the UK for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.
-
Eisai Presents New Data on the Relationship between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2b Study for Early Alzheimer's disease
11/4/2021
Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") announced today the presentation of data from the company's extensive Alzheimer's disease (AD) pipeline, including six oral presentations that will provide deeper insights into lecanemab's potential as a treatment for early AD.
-
Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences’ Lead Drug CandidateIt states, “No evidence of data manipulation was found for Western blot data.”
11/4/2021
Cassava Sciences, Inc. has been informed by the Journal of Neuroscience that there is no evidence of data manipulation in an article it published in July 2012 describing a new approach to treating Alzheimer's disease.
-
Qynapse to Sponsor and Present New Data on QyPredict® at Clinical Trials on Alzheimer's Disease Conference (CTAD 2021)
11/4/2021
Qynapse Inc. is pleased to sponsor the 14th Clinical Trials on Alzheimer's Disease conference (CTAD) to be held from November 9-12, 2021 , in Boston, MA.
-
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
11/4/2021
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
-
Perceiv AI to present Foresight AD a novel prognostic tool to optimize Alzheimer's clinical trials, at the 14th Clinical Trials on Alzheimer's Disease (CTAD 2021) conference
11/4/2021
Perceiv Research Inc. today announced that the company's representatives will be introducing Foresight AD TM , a prognostic tool for Alzheimer's Disease progression, at the 14th Clinical Trials in Alzheimer's Disease conference
-
This novel diagnostic technology uses augmented reality and a smartphone or tablet to administer cognitive and functional tests.